Market Overview:
The global contract pharmaceutical manufacturing market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing demand for generic drugs, rising prevalence of chronic diseases, and growing number of outsourcing agreements between big pharma and contract manufacturers. The global contract pharmaceutical manufacturing market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into API and FDF. The API segment is further sub-segmented into small molecules and biologics. The FDF segment is further sub-segmented into solid dosage forms (tablets/capsules), liquid dosage forms (syrups/suspensions), semi-solid dosage forms (creams/ointments), parenteral products (injectables/infusions), respiratory products (inhalers/nebulizers) and other FDFs). On the basis of application, the market is divided into specialty pharma or midsize companies, generics companies, big pharma companies, and other applications such as nutraceuticals & dietary supplements etc.).
Product Definition:
A contract pharmaceutical manufacturer is a company that manufactures prescription or over-the-counter drugs under contract for another company. Contract manufacturing is an important part of the pharmaceutical industry, as it allows smaller companies to focus on drug discovery and development, while larger companies can concentrate on marketing and sales.
API:
API is the abbreviation for Application Programming Interface. It is a set of commands and protocols used by software programs to communicate with each other. The API can be used to access data from a remote location which may require some input parameters. APIs are widely adopted in Contract Pharmaceutical Manufacturing (CPM) owing to its benefits such as cost-effectiveness, ease of use, and flexibility in terms of operations & functions offered by the software program.
FDF:
FDF (Fluid Drug Form) is a drug substance that is used to formulate solid dosage forms of drugs. It contains the active pharmaceutical ingredient and other excipients which are mixed with water or another medium in order to make a slurry. The mixture thus obtained is called the final product or finished dose formulation.
The FDF process involves three major steps namely; preparation of an API solution, incorporation into FDF.
Application Insights:
The specialty/midsize segment dominated the global contract pharmaceutical manufacturing market in 2017, accounting for over 45.0% share of the total revenue. The growth can be attributed to factors such as an increase in number of hospitals and clinics, growing demand for high quality medicines, and government initiatives that encourage production units to become involved in low-volume manufacturing.
Specialty/midsize manufacturers focus on R&D activities to develop new drugs and vaccines but also have a significant role in producing generic drugs that are widely used across various applications due to their low cost as well as high quality standards. This is anticipated to drive the product demand over the forecast period.
Regional Analysis:
North America dominated the global contract pharmaceutical manufacturing market in 2017. The presence of a large number of contract research organizations (CROs) and growing outsourcing activities are some factors contributing to the growth of this regional market. In addition, increasing R&D investments by major companies is expected to drive this regional CMO market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising healthcare expenditure, improving infrastructure in rural areas as well as cities, and an increase in disposable income levels throughout Asia Pacific region. Furthermore, government initiatives encouraging domestic production are expected to boost CMOs operating within APAC during the forecast period (2018-2030).
Growth Factors:
- Increasing demand for generic drugs due to their low cost and efficacy as compared to branded drugs
- Rising prevalence of chronic diseases such as cancer, diabetes, and heart diseases that require long-term treatment
- Growing number of biotechnology companies that are focusing on the development of novel therapeutics
- Proliferation of contract research organizations (CROs) that provide drug discovery and development services to pharmaceutical companies
- Emergence of personalized medicine that requires customized manufacturing of drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Contract Pharmaceutical Manufacturing Market Research Report
By Type
API, FDF
By Application
Specialty/Midsize, Generics, Big Pharma, Other
By Companies
Catalent, DPx, Lonza, Piramal Healthcare, Aenova, Jubilant, Famar, Boehringer Ingelheim, Fareva Holding, AbbVie, Nipro Corp, Vetter, Sopharma, DPT Laboratories, Recipharm, NextPharma, Dishman, Aesica
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Contract Pharmaceutical Manufacturing Market Report Segments:
The global Contract Pharmaceutical Manufacturing market is segmented on the basis of:
Types
API, FDF
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Specialty/Midsize, Generics, Big Pharma, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Catalent
- DPx
- Lonza
- Piramal Healthcare
- Aenova
- Jubilant
- Famar
- Boehringer Ingelheim
- Fareva Holding
- AbbVie
- Nipro Corp
- Vetter
- Sopharma
- DPT Laboratories
- Recipharm
- NextPharma
- Dishman
- Aesica
Highlights of The Contract Pharmaceutical Manufacturing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- API
- FDF
- By Application:
- Specialty/Midsize
- Generics
- Big Pharma
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Contract Pharmaceutical Manufacturing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Contract Pharmaceutical Manufacturing is a manufacturing process that allows pharmaceutical companies to produce their products outside of the United States. This service helps to reduce costs and speed up product development times.
Some of the major companies in the contract pharmaceutical manufacturing market are Catalent, DPx, Lonza, Piramal Healthcare, Aenova, Jubilant, Famar, Boehringer Ingelheim, Fareva Holding, AbbVie, Nipro Corp, Vetter, Sopharma, DPT Laboratories, Recipharm, NextPharma, Dishman, Aesica.
The contract pharmaceutical manufacturing market is expected to grow at a compound annual growth rate of 6.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Contract Pharmaceutical Manufacturing Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Contract Pharmaceutical Manufacturing Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Contract Pharmaceutical Manufacturing Market - Supply Chain
4.5. Global Contract Pharmaceutical Manufacturing Market Forecast
4.5.1. Contract Pharmaceutical Manufacturing Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Contract Pharmaceutical Manufacturing Market Size (000 Units) and Y-o-Y Growth
4.5.3. Contract Pharmaceutical Manufacturing Market Absolute $ Opportunity
5. Global Contract Pharmaceutical Manufacturing Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Contract Pharmaceutical Manufacturing Market Size and Volume Forecast by Type
5.3.1. API
5.3.2. FDF
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Contract Pharmaceutical Manufacturing Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Contract Pharmaceutical Manufacturing Market Size and Volume Forecast by Application
6.3.1. Specialty/Midsize
6.3.2. Generics
6.3.3. Big Pharma
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Contract Pharmaceutical Manufacturing Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Contract Pharmaceutical Manufacturing Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Contract Pharmaceutical Manufacturing Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Contract Pharmaceutical Manufacturing Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Contract Pharmaceutical Manufacturing Demand Share Forecast, 2019-2026
9. North America Contract Pharmaceutical Manufacturing Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Contract Pharmaceutical Manufacturing Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Contract Pharmaceutical Manufacturing Market Size and Volume Forecast by Application
9.4.1. Specialty/Midsize
9.4.2. Generics
9.4.3. Big Pharma
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Contract Pharmaceutical Manufacturing Market Size and Volume Forecast by Type
9.7.1. API
9.7.2. FDF
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Contract Pharmaceutical Manufacturing Demand Share Forecast, 2019-2026
10. Latin America Contract Pharmaceutical Manufacturing Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Contract Pharmaceutical Manufacturing Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Contract Pharmaceutical Manufacturing Market Size and Volume Forecast by Application
10.4.1. Specialty/Midsize
10.4.2. Generics
10.4.3. Big Pharma
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Contract Pharmaceutical Manufacturing Market Size and Volume Forecast by Type
10.7.1. API
10.7.2. FDF
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Contract Pharmaceutical Manufacturing Demand Share Forecast, 2019-2026
11. Europe Contract Pharmaceutical Manufacturing Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Contract Pharmaceutical Manufacturing Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Contract Pharmaceutical Manufacturing Market Size and Volume Forecast by Application
11.4.1. Specialty/Midsize
11.4.2. Generics
11.4.3. Big Pharma
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Contract Pharmaceutical Manufacturing Market Size and Volume Forecst by Type
11.7.1. API
11.7.2. FDF
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Contract Pharmaceutical Manufacturing Demand Share, 2019-2026
12. Asia Pacific Contract Pharmaceutical Manufacturing Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Contract Pharmaceutical Manufacturing Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Contract Pharmaceutical Manufacturing Market Size and Volume Forecast by Application
12.4.1. Specialty/Midsize
12.4.2. Generics
12.4.3. Big Pharma
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Contract Pharmaceutical Manufacturing Market Size and Volume Forecast by Type
12.7.1. API
12.7.2. FDF
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Contract Pharmaceutical Manufacturing Demand Share, 2019-2026
13. Middle East & Africa Contract Pharmaceutical Manufacturing Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Contract Pharmaceutical Manufacturing Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Contract Pharmaceutical Manufacturing Market Size and Volume Forecast by Application
13.4.1. Specialty/Midsize
13.4.2. Generics
13.4.3. Big Pharma
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Contract Pharmaceutical Manufacturing Market Size and Volume Forecast by Type
13.7.1. API
13.7.2. FDF
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Contract Pharmaceutical Manufacturing Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Contract Pharmaceutical Manufacturing Market: Market Share Analysis
14.2. Contract Pharmaceutical Manufacturing Distributors and Customers
14.3. Contract Pharmaceutical Manufacturing Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Catalent
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. DPx
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Lonza
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Piramal Healthcare
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Aenova
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Jubilant
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Famar
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Boehringer Ingelheim
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Fareva Holding
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. AbbVie
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Nipro Corp
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Vetter
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Sopharma
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. DPT Laboratories
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Recipharm
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. NextPharma
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Dishman
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Aesica
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
